COMPASS Pathways Q2 2023 Earnings Call Transcript

Quartr
Provided by Quartr
August 3, 2023

There are 12 speakers on the call.

Operator

Day, ladies and gentlemen, and welcome to the Compass Pathways Second Quarter 723 Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Stephen Schultz. You may begin.

Speaker 1

Welcome all of you and thank you for joining us today for our Q2 2023 results conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. And today, I'm joined by Kabir Nath, our Chief Executive Officer Mike Falvey, our Chief Financial Officer and Doctor. Guy Goodwin, our Chief Medical Officer. This call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call.

Speaker 1

Before we begin, Let me remind everyone that during the call today, the team will be making forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. You should not place undue reliance on these forward looking statements. Actual events or results could differ materially from those expressed or implied by any forward looking statements as a result of various risks, uncertainties and other factors, including those risks and uncertainties described under the heading Risk Factors in our quarterly report on Form 10 Q filed with the U. S. Securities and Exchange Commission and in subsequent filings made by Compass with the SEC.

Speaker 1

Additionally, these forward looking statements represent Our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward looking statement, even if our estimates or assumptions change. I'll now hand the call over to Kabir Nath.

Speaker 2

Thank you, Steve. Good day, everyone, and thank you for joining us. During this past quarter, Compass Pathways has continued to achieve strong results across important aspects of our business. I will cover the progress of our trials as well as commercial updates. Guy will talk about encouraging regulatory and clinical news, And Mike will address the excellent progress we have made to extend our financial runway.

Speaker 2

Our Phase 3 trials in treatment resistant depression COMF-five and COMF-six are ongoing and remain on track for primary endpoint readouts In summer 2024 and mid-twenty 25 respectively. Both studies are on track and in line with our expectations with some patients having now progressed to Part B for both studies. 2 thirds of the COM-five sites have been initiated. I'll remind you that these are the largest, most robust trials ever conducted To evaluate the use of psilocybin treatment or indeed any psychedelic drug and the trials are designed to support an NDA submission to the FDA. We noted in the Q1 that the American Medical Association has accepted a current procedural terminology Or CPT-three code for psychedelic therapies.

Speaker 2

In the Q2, as it happens on the last day of the quarter, The actual code language was released. As we have indicated, this language specifically provides physicians And other qualified healthcare professionals with a means to track the work involved in and ultimately seek reimbursement for Delivering support for psychedelic treatments. We hosted a webinar on this development, which included experts from both the payer and treatment delivery communities. I hope you had a chance to watch the program, which is archived on our website in the Investor section. We believe the language of the CPT-three tracking code It's particularly well aligned with the requirements of COM360 psilocybin treatment and a crucial step toward a reimbursed CPT code That covers psychological support for therapies like COM360 subject to FDA approval.

Speaker 2

Most importantly, It's a key step towards enabling broad and equitable access to psychedelic treatments. Without CPT codes, It will be challenging to obtain reimbursement by CMS and health plans in the U. S. For the psychological support Provided during the administration of COM360, which would result in a severe limitation of access to new and effective treatments That require in person support. This CPT-three code is an important recent development That supports the commercial landscape into which we plan to launch Comp360.

Speaker 2

We also saw this quarter That esketamine sold under the brand name Spravato has now achieved sales of $255,000,000 For the first half of the year in the U. S. With quarter over quarter growth of roughly 30% and year over year growth of over 80%. We believe that this demonstrates the level of unmet need in treatment resistant depression. This growth is also driven By the increasing interest in mechanisms which offer rapid treatment effect as well as the scaling of the infrastructure of interventional psychiatry facilities And other treatment centers.

Speaker 2

These are the types of facilities that we believe would be able to deliver COMF360 treatment if approved. Also in this quarter, the U. S. Patent Trial and Appeal Board reaffirmed decisions to uphold 2 key patents, The 257 and 259 patents, which cover the COMF360 crystalline silicidinpolymorph A. Intellectual property is a key element of our overall commercial protection for COM360 and central to our work in developing innovative treatments For therapeutic areas of significant unmet medical need, we were pleased with this decision as it marks the conclusion of what had been outstanding challenges to these patents.

Speaker 2

I'll now hand over to Guy to update you on regulatory and clinical news during the quarter. Guy?

Speaker 3

Thank you, Kabir. In the past quarter, the FDA issued draft guidance on the development of psychedelic medicines To address the unique features of this class of treatment, we are pleased that this guidance is well aligned with the COM360 Phase 3 program design and includes many of the points that we have discussed with the agency. We believe this guidance is important validation The FDA is supportive of a robust and appropriate development path for novel psychedelic based treatment like COM360. A particular note in the FDA guidance is the use of psychotherapy, where the agency cautions Such interventions may complicate the assessment of clinical trials. I will note that COM360 treatment is not designed to utilize psychotherapy, but instead psychological support, which primarily focuses on safeguarding patients.

Speaker 3

In fact, we think it is inappropriate to refer to psilocybin treatment as psychedelic assisted psychotherapy as commonly occurred. Regulators generally evaluate and approve investigational drug candidates based on quality, safety and efficacy. They have not historically evaluated or regulated psychotherapy. Our approach is clear To achieve regulatory approval, the drug effect needs to be established unambiguously in clinical trials, which is only possible if any psychological support is applied in a consistent way and is not an alternative treatment itself. A recent opinion piece we published with academic colleagues in the American Journal of Psychiatry goes into more detail about this important distinction.

Speaker 3

The evidence we have seen from rigorous studies of psilocybin treatment to date leads us to believe that the potential therapeutic effect of psilocybin treatment comes primarily from the drug itself, while psychological support is essential for safeguarding patients before, during and after administration. Psychological support is not independent psychotherapy as commonly understood. The intense psychedelic states Turning to our clinical studies. In July, the journal Neuropsychopharmacology published our data from an open label study That suggested that the use of selective serotonin reuptake inhibitors or FSRI antidepressant does not interfere with the As we have remarked previously, this finding, if confirmed, May prove to have important indications for the eventual real world use of COM360 because it could offer patients potentially greater choice And how far they withdraw from other drugs before treatment with COM360 in the future. Beyond treatment resistant depression, our Phase 2 studies in PTSD and anorexia nervosa continue to progress well With PTSD data expected this year, it is still too early to provide readout guidance for the anorexia nervosa study, Which is now making much better progress after amendment to our protocol.

Speaker 3

We will update you regarding timing on future calls. Looking beyond our sponsored trial to investigate the initiated study, we continue to see encouraging data emerge. For example, a study of cancer patients with depression who received a single dose of COM360 psilocybin treatment Was presented at this year's ASCO meeting and a study demonstrating the potential for COM360 siliciden treatment in female patients With anorexia nervosa was published in Nature Medicine. These data support the robust knowledge base Compass is developing around our COM360 treatment. Moreover, this preliminary research can be an important step In finding new and better options for patients with difficult to treat conditions.

Speaker 2

I will now hand the

Speaker 3

call to Mike for the financial overview. Mike?

Speaker 4

Thank you, Guy. I'll now recap the highlights of our Q2 financial results. Comparing this year to last For the Q2 of 2023, net loss was $28,300,000 or $0.62 per share, Including non cash share based compensation of $4,600,000 compared to net loss of $21,000,000 or $0.50 per share, including non cash share based compensation of $3,200,000 for Q2 2022. R and D expenses increased to $19,800,000 in Q2 2023 compared with $15,900,000 in Q2 last year. G and A expenses increased to $12,800,000 in Q2 2023 compared to $11,300,000 in Q2 2022.

Speaker 4

I'll now turn to analysis of our current second quarter results compared to the prior Q1 results. Our current quarter financial results reflect our continued success in advancing our Phase 3 trials in treatment resistant depression and encouraging progress in extending our cash runway. In line with our expectations, cash used in operations in the 2nd quarter Was $24,800,000 in the middle of the guidance range we provided last quarter. In this quarter, Net loss was $28,300,000 or $0.62 per share compared with a net loss of $24,200,000 or $0.57 per share for the prior quarter. These results include non cash share based compensation of $4,600,000 in this quarter and $4,100,000 in the prior quarter.

Speaker 4

R and D expenses were $19,800,000 in this quarter compared with $19,000,000 in the prior quarter. The increase was mainly due to external development expenses related to our Phase 3 program. Other expenses also increased. G and A expenses were consistent in both quarters at $12,800,000 Turning to our balance sheet. Cash increased by $31,100,000 in the Q2 of 2023 As financing activities generated $55,900,000 At the end of June, we concluded a potential $50,000,000 debt facility with Capital and drew down $28,800,000 net of issuance costs.

Speaker 4

Earlier in the quarter, We raised an additional $26,900,000 from the sale of shares under our ATM facility. This financing activity was offset by net cash used in operating activities of $24,800,000 Regarding Q3 financial guidance, we expect 2 factors to create an unusually low range for cash used in operations, which we expect will return to a more conventional level in the Q4 and beyond. We expect the 3rd quarter net cash used in Operating activities to be between minus $2,000,000 and positive $18,000,000 First, We have completed contracts with our vendors, reflecting the final Phase 3 trial design. As a result, We will be able to reduce the balance of our prepaid costs, which will reduce our cash used in operations in the Q3 by close to $10,000,000 2nd, we are expecting to receive our estimated $14,000,000 2022 U. K.

Speaker 4

R and D tax credit in the 3rd quarter. The low end of our guidance reflects the receipt of these funds in Q3 and the top end of the guidance reflects the funds being delayed until Q4. Turning to full year financial guidance. We are narrowing the range for cash used in operation to be between $80,000,000 $90,000,000 We have narrowed our full year range as a result of improved clarity around the scale and the timing of expected Phase 3 costs and continued spending discipline in light of continued market uncertainty. Compass continues to maintain a strong financial position With cash and cash equivalents of $148,200,000 at June 30, 2023 compared with $143,200,000 At December 31, 2022, we have recognized long term debt on our balance sheet for the first time as a result of the debt facility with Hercules Capital, which we initiated in the Q2.

Speaker 4

We continue to view our strong balance sheet as an important strategic asset, which we plan to manage carefully as we invest to advance these promising potential treatments, while at the same time continuing to create value for our shareholders. Thank you. And I'll now turn the call back to Hamir.

Speaker 2

Thanks, Mike. We're pleased with our ongoing progress and continue to be conscious of the importance and responsibility of our leadership In the development of investigational psychedelic treatments, which we believe represent the next generation of mental health Therapeutic options. Importantly, our Phase 3 program in treatment resistant depression is our clear focus And is progressing on track and in line with our expectations. As we move through the clinical program And as we observe the commercial rollout of SPRAVATO, we're encouraged by an increasingly supportive alignment in the treatment network infrastructure That's developed significantly since the SPRAVATO launch. We believe that this reflects a treatment paradigm that is here to stay And we would expect much of this infrastructure to be relevant to Comp360 as well.

Speaker 2

In closing, I want to offer a heartfelt thank you to one of our co founders, Doctor. Ekaterina Malevskaya, who recently stepped down from her executive role as Chief Innovation Officer. Together with George Goldsmith and Lars Wilder, Katya co founded Compass Pathways in 2017, determined to bring much needed innovation to the field of mental healthcare. Catia leaves an indelible mark on the company she helped found. Compass today reflects both the rigor and precision one would expect from a scientist And the compassion for and commitment to patients that one would expect from a physician.

Speaker 2

Our influence extends well beyond our company To the fields of psychedelic medicine and mental healthcare, we're closer to meaningful breakthroughs in care for patients, thanks to her work. We're pleased that we'll continue to benefit from her experience and insights as she remains on the Compass Board of Directors. And I know that I speak on behalf of the entire Compass team in thanking her for her extraordinary vision, leadership and encouragement. Thank you once again for your participation in today's call. We'll now turn to Q and A.

Speaker 2

So I will hand this call back to the operator.

Operator

Thank you. Our first question comes from Ritu Baral with TD Cowen. Your line is open.

Speaker 5

Hi, guys. This is Athena on for 2, thanks for taking my questions. To start off, I noted in the 8 ks you issued today that Eitai has requested that Compass register their shares. Could you provide any color on that request? And I have a follow-up question after this one.

Speaker 5

Thanks.

Speaker 2

Thanks, Athena. It's Kabir. Just checking, you can hear me clearly?

Speaker 5

Yes.

Speaker 2

Great. So our understanding is that for Atai, this is a matter of regular corporate housekeeping.

Speaker 5

Got it. And my next question goes back To the CPT codes, is there a level 1 code that exists that is maybe a good comparison for how you see the new We understand from KOLs that they often use some existing codes to cover Ketamine administration. What are those and what do they reimburse at?

Speaker 2

Thank you for the question. So yes, certainly, if we look at The history of Ketamine prescribing or indeed ex Ketamine once Janssen launched SPRAVATO because No specific codes were applied for or approved for those. It is absolutely the case that Providers have had to make do with existing codes. And I can't give you the specific details of which codes they use, We're happy to follow-up with that in more detail in future. I think what's important to note is for us, we recognize that what we are doing is unique.

Speaker 2

The 6 to 8 hour support required for psilocybin demanded that we actually do Seek approval for, as we now have received, a new code. And as you'll be aware, this new CBT3 code Provides for on an hourly basis the tracking of the support that's required for psychedelic medications. And therefore, we're confident that this code will apply very much to us for the future, but also potentially For other products that would require similar extended support such as MDMA, if that would be approved for MDMA assisted therapy. Important to note though that the preparation and integration sessions that are also required for COM360 psilocybin treatment We'll also be covered by existing codes. They will be covered by existing psychotherapy codes.

Speaker 5

Got it. Thank you. I'll hop back in the queue.

Speaker 2

Thanks, Opita.

Operator

Thank you. Our next question comes from Charles Duncan with Cantor. Your line is open.

Speaker 6

Hey, good morning. Thanks for taking our question early and congrats on the progress in the quarter, Kabir and team. I basically had 3 quick questions on the ongoing COMF-five and 6 Trials, I'll just rattle them off quickly and you can take them in order if you want. The first is, are you seeing any, I'll call it rate limiter in terms of SSRI use and weeding off that in terms of enrollment In those trials, the second is for Part B progression, are you seeing any differences in the Option for retreatment thus far, I know it's probably early, you probably don't have a lot of patients, but differences between the two trials. And third question quickly is for Part C, you probably aren't quite there yet, but have you had any patients enroll in Part C or are you near to enrolling patients in Part C having gotten through week 26 in Part B?

Speaker 6

Thanks.

Speaker 2

Thanks, Charles. So I'll start and if Guy has any color to add, I'll ask him to jump in. So no, I mean, It's been very clear in our protocol both in 2b and in Phase III that the washout is required. These are monotherapy trials. So far, we're not seeing any experience that's very different from what we saw in 2b.

Speaker 2

Obviously, for some patients, this is a significant issue, and we Saw that in Part 2b and we will see it in Part 3 as part of the prescreening and the screening. But it remains the fact that these are monotherapy trials. And again, So far, the experience is consistent from our last trial to this one. In terms of Part B and Part C, The numbers are not where I'm in a position to give you an answer on those at this stage. I'll just go back to what I said.

Speaker 2

We're on track, in line with our expectations with group.

Speaker 3

Hi, I think I don't think so.

Speaker 2

Okay. Thank you. Thanks, Charles.

Speaker 7

Thank you.

Operator

Thank you. Our next question comes from Patrick Trucchio with H. C. Wainwright. Your line is open.

Speaker 8

Thanks and good morning and congrats on all the progress. So several studies have been published recently as noted in today's press release. I'm wondering if you could talk about the level of interest or acceptance in psilocybin therapy, specifically among neuropsych key opinion leaders and clinical trial investigators and How these views have changed, if at all? And how do you view this evolution of views progressing as we get closer to that Phase 3 readout next year?

Speaker 2

Thanks, Patrick. I will pass that to Guy.

Speaker 3

Thanks, Patrick. I think there's been a consolidation rather than a change. I think people are a bit clearer now about what's actually required. We've worked pretty hard to emphasize our Innovation and our forward looking in this field and to also emphasize that our reliance is on data. I think that's respected and I think that's one of the ways we get progress.

Speaker 3

And of course, that speed is what we really want in terms of getting this to patients as soon as possible. I mean, clearly, there's no immediate possibility that patients that the clinicians of the kind you're describing can use the treatment. So it remains for most of them a little hypothetical, but the interest is still there. And I think as we move forward with this greater evidence around The prevalence of TRD, the unmet need that is clearly there, I think that's been an important change really just in the last year or 2 With really quite influential reviews that have highlighted that change. And I think that underlies more than anything, the increased use of SPRAVATO.

Speaker 8

Yes. Can you talk a little bit more about the PTAB decision and the commentary around outstanding challenges to COM360 patents? Specifically, I'd like to know how we should think about the durability of COM360 IP, particularly against future potential challenges following this PTAB decision?

Speaker 2

Yes. So Patrick, I mean, to be clear, what this PTAB decision does is it upholds the validity of our patents and it exhausts All the remaining lines of challenge or appeal against these patents. From our perspective, that clearly does Increase our confidence that these are robust patents that we will be able to defend in future in our commercial world, But we've always believed that these are robust patents that give us significant protection based on the extensive work we did to arrive at Polymorph Bay.

Speaker 8

Great. Thank you so much.

Operator

Thank you. Our next question comes from Francois Francois with Oppenheimer, your line is open.

Speaker 9

Hi. Thanks for taking the questions. Just to start here, I was just wondering, can you Talk about your comfort with these trials kind of being the last potential trials in order to submit just based around the fact that You do have a washout period and the SSRS situation. Is this something that's evolving or are people comfortable with the monotherapy and the washout?

Speaker 2

So I'll start. One thing to note, and we did note, I mean, it's a small study, but we did actually publish during this quarter A paper of 19 patients on psilocybin on a background of SSRIs and we saw no diminution of effect. So that's an important piece Data as Guy noted, which needs to be confirmed on a larger scale. I think it's clear from the point of view of really demonstrating the efficacy and safety of COM3 But monotherapy is the right way to study it. What we've also commented in the past though is, as you look at the design of Part B and Part C, There will be data in patients who have gone back on antidepressants to subsequently take COM360.

Speaker 2

And to your question, we recognize that, that May reflect some of what happens in the real world. Guy?

Speaker 3

Yes. I think just on the point of view and the question also I did earlier to the difficulties that it poses having to withdraw people. It is worth remembering that the Phase 2 study had exactly the same approach And that was successful and particularly in the latter part of that study really had an accelerating recruitment rate. So I think we remain Comfortable that that's the right way to go in view of the theoretical need to demonstrate efficacy without a background of other drugs.

Speaker 9

Do you on that note, do you see a difference here in terms of the monotherapy approach for TRD versus MDD when by definition Patients with TRD have failed multiple approaches or is this TRD and MDD are probably going to be taken in a similar context?

Speaker 3

That's a good question for which I don't think we yet have an answer. The answer will really be based on our future experience, Particularly in the second and third phases of our trials, and in 6 where there'll be 2 treatments. I mean the issue of whether there will be a need for continuing treatment, I think at the moment is open. The differences between MDD and TRD essentially Reflect the fact that MDD is an easier condition to treat. There is no unmet need and that there are treatments already available.

Speaker 3

The difference obviously with TRD is it's harder to treat and people have exhausted often the obvious treatments with MDD.

Speaker 9

Okay, great. And just maybe for those less familiar here, can you just touch on the we talked about SPRAVATO and esketamine Kind of take off here and how things are going and the correlation with you guys. Can you just maybe help us understand the compare and contrast, Especially the differences here with your approach versus SPRAVATO.

Speaker 2

So Clearly, for esketamine, it is a somewhat dissociative drug and the requirement is for a monitoring period after the self administration of Clearly, with psilocybin, what we require is psychological support during the administration of the drug, which is

Speaker 4

a 6 to 8 hour session.

Speaker 2

However, the similarities and the reason we refer to this as demonstrating the growth of the infrastructure or the scaling of the infrastructure It does require for esketamine a dedicated space. It does require the place for the patient to be. It requires some tying up of provider resources. And Not only that, I think from a provider and infrastructure perspective, but also a very important point that the acceptance Of a rapidly acting novel mechanism in this space is also very important to us. So I think that's where we would leave it for now.

Speaker 3

I think I would just add, of course, the number of visits required for the patient is really substantial in the case of ketamine or esketamine. So as of the moment, we're looking at 1 we're trialing 1 or 2 visits for the treatment with COM360.

Speaker 9

That's very helpful. Thank you.

Speaker 7

Thanks, Frank.

Operator

Thank you. Our next question comes from Elmer Piros with EFH. Your line is open.

Speaker 7

Yes. Good afternoon. Good morning. Can you hear me?

Speaker 2

Yes, we can, Alamo.

Speaker 7

Yes. Thank you. Just wanted to confirm a couple of things about the PTSD study, Kamir. Is this a single dose that you administered to patients?

Speaker 3

Yes, it is, Eleman.

Speaker 7

Yes. And is there a similar psychological support that is provided in preparation During the administration and maybe one follow-up session similarly to your TRD study?

Speaker 3

The design is very similar to the TRD study. We are obviously interested in the experience both of the patients and the therapist with this very different condition, But our psychological support is intended to be pretty generic. And of course, as we've explained at some length, it is essentially about safety And safeguarding, and it doesn't really deal with different psychopathologies.

Speaker 7

Yes. So Guy, if I remember correctly, the FDA sort of lumped together in their draft guidance, Psychological support and psychotherapy or they may have used the term end, Do you think that there is an onus on you to demonstrate that there is no significant effect, therapeutic effect, Our clinical benefit from the support component?

Speaker 3

I think we're under I think we have an obligation to demonstrate The effects we observe are primarily attributed to the drug. I think we do that by using a multiple dosage regime, which was Present in Phase 2 and will also be in 6. And we think that that comparison between one dose and another is the key to efficacy. It is of course crucial that the psychological support is equivalent in the two cases, both before, during and after the administration of the drug. And we think that our procedures for monitoring that are going to ensure that we can demonstrate that we are indeed delivering Psychological support, which is consistent in all those phases of the treatment.

Speaker 3

I think what the FDA has asked further to that It's rather difficult and suggesting factorial designs and various variations in the therapist. We think that's difficult and will be of great interest if the academic sector wants to take that up, and we will be interested in the results when they do.

Speaker 7

Yes. Thank you. And I was just wondering how accurate perhaps clinicaltrials dot gov Yes, at the moment, I see 11 15 U. S. Sites as marked as a recruiting.

Speaker 7

Probably there is some overlap between the 2 Phase 3 studies. Is this roughly accurate as a snapshot of the current situation,

Speaker 2

Yes. Certainly, as we said on 5, more than 2 thirds of sites have now been initiated. And I'd remind you that 5 is a U. S. Only trial.

Speaker 2

6 is clearly a global trial. We have U. S. Sites up and running at the moment, yes.

Speaker 7

And what would be the rate limiting

Speaker 2

We're getting approvals. And so That process is well underway. We do have approvals in some other countries already outside the states, but that process is well underway and again exactly in line with our expectation For the recruitment of 6.

Speaker 7

I see. Thank you so much for taking my questions.

Speaker 2

Thanks, Elemer.

Operator

Thank you. Our next question comes from Tom Shrader with BTIG. Your line is open.

Speaker 10

Thanks for taking the question. I was going to follow on Ellie's vein in PTSD. How large is this opportunity? Who are the patients? Are they mostly military?

Speaker 10

And do a lot of them also have a diagnosis of depression? And what I'm kind of getting at is, Do you see this as a separate indication or would this be a subset of patients where the approach depressed patients where the approach was Particularly appropriate and is the hope here to get into the VA system where it might be an attractive option? Thanks.

Speaker 3

Yes. So if I can take that, I mean, currently, it's not orientated specifically to the VA system. And that obviously is a great If interest to us in the future, at the moment, we're interested in the experience, the feasibility of doing these studies in this new indication. And we will know obviously after we completed this simple study, whether it is feasible. I think you can see it in 2 ways.

Speaker 3

In fact, it is a separate indication potentially, but also it's an important comorbidity. We have an IIS, which will soon be reporting from California, which has recruited from the VA system Patients with treatment resistant depression, we anticipate there will be a great deal of comorbidity with PTSD in that group. So to answer your question, we're interested in both conditions, both PTSD independently, which is what we're studying in London and New York. And we're interested in TRD with co morbid PTSD, which of course is highly relevant to the VA population.

Speaker 10

Got it. Thank you.

Operator

Thank you. Our next question comes from Kyle Kin with Canaccord Genuity. Your line is open.

Speaker 4

Hello. This is Kyle speaking for Sumant Kulkarni. 2 from us. How closely are you watching the potential for BiogenSage in the ranolum that might get approved later this week? We're asking because there could be some relevance to the use of psychedelic therapeutics in depression as an Approval there could pave the way for more episodic treatment for depression versus chronic treatment.

Speaker 2

Thanks, Carl. So yes, I completely agree with you. If ziranolone is in fact approved for MDD and I know there's a lot of Debates in the community around how likely that is? Absolutely. I mean, it is an interesting paradigm of a rapid acting with episodic retreatment On demand as it were on relapse, we would absolutely be observing that with interest to see What sort of acceptance that has, how Sage end up positioned it?

Speaker 2

So yes, we are very well aware of that.

Speaker 4

Okay, great. And then one more. With the knowledge that COM360 and MAT's MDMA for PTSD have several differences in the respective programs, What are the types of results that COM360 might need to achieve on the CAHPS V for COM360 to be competitive? And what would you need to see in your ongoing Phase 2 that might give you more confidence to proceed into Phase 3?

Speaker 3

Well, CAHPS V is our endpoint or one of our endpoints in that study. So we'll have some idea of how to power any subsequent study. Clearly, the relative efficacy is best established in a head to head comparison, and we're a long way from Doing that, I suspect. So I think we will simply have to take it as it comes. We remain very interested in the indication, It's a little premature to try and think how we would compare with MAP.

Speaker 3

So there's also quite an important difference in the demands for therapist time And indeed for the patient time between the two approaches. So it's going to be a highly pragmatic comparison if an amendment is left now.

Speaker 4

Okay, great. Thanks.

Operator

Thank you. Our next question comes from Jason McCarthy with Maxim Group. Your line is open.

Speaker 11

Hey, this is Michael Okunovich on the line for Jason McCarthy. Thank you for taking my questions today. So I guess to start off, I'd just like to see if you could provide a bit of commentary on why you think we're seeing some stronger traction from SPRAVATO. Is this owing largely to greater acceptance of interventional approaches, the maturing delivery infrastructure Or the maturing reimbursement environment. I'd just like to see if I can get your take on that.

Speaker 2

I think all 3 would be Frankly, the answer. I mean, I think a couple of things. All of those are relevant. Growth of infrastructure, increasing acceptance by psychiatrists and other health care providers, as well as I think what is a broadly favorable reimbursement landscape for SPRAVATO. I think the other element though is that acceptance is actually driven by the results that people are seeing and the fact that results typically Seem to be stronger than they perhaps were in the clinical trials.

Speaker 2

So what was seen as marginal efficacy in the trials have actually translated into better Results in the real world and greater stickiness, that's the additional factor I would add.

Speaker 3

I think the clinical experience certainly that I had With Ketamine in the past, it's just the speed of response and the completeness of the response. That is very, very striking to clinicians. And I think once seen, you don't really forget And I think that's the impact. Graphs don't really capture it. When you see the patients live, you get a sense of their recovery and their joy to be relieved of their symptoms.

Speaker 3

That's Very special and that drives the uptake of these fast acting drugs.

Speaker 2

All right.

Speaker 1

Yes, thank you for that.

Speaker 11

And then just one more as kind of a housekeeping question and I'll hop back in the queue. I'd just like to see if you could remind us how much remains on your ATM?

Speaker 4

Sure. So the full ATM was $150,000,000 and since inception, we've raised about

Speaker 6

$28,000,000 So, that would leave about $122,000,000 remaining.

Speaker 2

All right.

Speaker 11

Thank you for that and congratulations on the progress this quarter.

Speaker 2

Thanks, Mike. Thank you.

Operator

Thank you. There are no further questions. I'd like to turn the call back over to management for any closing remarks.

Speaker 2

Thanks very much. So thank you everyone for your participation on today's call. As you heard and came through in the questions, this has been a strong quarter for us. Excellent progress in terms of the Phase III trials being underway, A fair amount of interesting new clinical data being published. Also, the significant moves we have made to extend our financial runway For both the use of the ATM and signing the debt facility with Hercules.

Speaker 2

So we're in a strong position going forward with a strong balance sheet, And we'll look forward to reporting back to you on continued progress in the next quarter. Thanks very much all for your time today.

Operator

Thank you for your participation. This does conclude the program and you may now disconnect. Everyone have a great day.

Powered by Quartr

Key Takeaways

  • Our Phase 3 trials in treatment-resistant depression COMF-five and COMF-six are on track with primary endpoint readouts expected in summer 2024 and mid-2025, and two-thirds of COMF-five sites initiated.
  • The AMA’s new CPT-3 tracking code for psychedelic therapies was released, providing a reimbursement path for the 6–8 hour psychological support sessions integral to COMP360 commercial rollout.
  • U.S. sales of esketamine (Spravato) reached $255 million in H1 2023, up ~30% QoQ and >80% YoY, highlighting rapid-acting mechanisms and growing interventional psychiatry infrastructure.
  • The U.S. Patent Trial and Appeal Board reaffirmed two key patents covering the COMP360 crystalline psilocybin polymorph A, concluding outstanding challenges and strengthening our IP position.
  • In Q2 we reported a net loss of $28.3 million, extended our cash runway with $26.9 million under our ATM program and a $50 million debt facility, leaving $148.2 million in cash as of June 30 and narrowing 2023 cash-use guidance to $80–90 million.
AI Generated. May Contain Errors.
Earnings Conference Call
COMPASS Pathways Q2 2023
00:00 / 00:00